325 related articles for article (PubMed ID: 32185681)
21. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab shows clinical activity in Hodgkin's lymphoma.
Bagcchi S
Lancet Oncol; 2015 Mar; 16(3):e108. PubMed ID: 25639369
[No Abstract] [Full Text] [Related]
23. Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.
Minson A; Douglas G; Bilmon I; Grigg A
Br J Haematol; 2019 Mar; 184(5):840-844. PubMed ID: 29532918
[No Abstract] [Full Text] [Related]
24. Retifanlimab: First Approval.
Kang C
Drugs; 2023 Jun; 83(8):731-737. PubMed ID: 37184754
[TBL] [Abstract][Full Text] [Related]
25. [Acute myocarditis caused by anti-PD-1 monoclonal antibody in the treatment of refractory Hodgkin lymphoma: a case report].
Shi XL; Wang D; Xu B; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):424-425. PubMed ID: 32482034
[No Abstract] [Full Text] [Related]
26. Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS; Savoldo B
Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
[TBL] [Abstract][Full Text] [Related]
27. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
29. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
31. Novel treatment concepts in Hodgkin lymphoma.
Glimelius I; Diepstra A
J Intern Med; 2017 Mar; 281(3):247-260. PubMed ID: 27991731
[TBL] [Abstract][Full Text] [Related]
32. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
33. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
[TBL] [Abstract][Full Text] [Related]
34. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
35. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
36. PD-1 inhibitors effective in hodgkin lymphoma.
Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882
[No Abstract] [Full Text] [Related]
37. Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.
Baues C; Semrau R; Gaipl US; Bröckelmann PJ; Rosenbrock J; Engert A; Marnitz S
Strahlenther Onkol; 2017 Feb; 193(2):95-99. PubMed ID: 27704149
[TBL] [Abstract][Full Text] [Related]
38. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
[TBL] [Abstract][Full Text] [Related]
39. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
[TBL] [Abstract][Full Text] [Related]
40. Cadonilimab: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1333-1339. PubMed ID: 35986837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
